Clinical efficacy in urinary tract infections and pharmacokineticsin impaired renal function of ritipenem acoxil

Abstract

We studied ritipenem acoxil (RIPM-AC), a new oral penem, for its clinical efficacy incomplicated urinary tract infection and its pharmacokinetics in patients with impaired renalfunction. The results were as follows. 1. In 10 patients with impaired renal function, blood levels and urinary excretion after oraladministration were investigated. Clear differences were observed between patients with severelyimpaired renal function and healthy volunteers. 2. Ten patients with complicated urinary tract infection were treated with 600 mg per day of RIPM-AC for 5 to 14 days. According to the criteria proposed by the Japanese UTI Committee, theclinical efficacy of RIPM-AC was excellent in 4, moderate in 1 and poor in 2. Neither clinicaladverse effects nor abnormal laboratory findings associated with RIPM-AC treatment wereobserved. © 1995, Japanese Society of Chemotherapy. All rights reserved.